endogenous retrovirus group K9, member 11Genealiases: []
Q-omics provides the consensus-scored ERVK9-11 profile across patient tissues and cancer cell-line models. ERVK9-11 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ERVK9-11 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, ERVK9-11 RNA expression shows 15,689 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KICH, and TGCT as cancer lineages where ERVK9-11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVK9-11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVK9-11 survival associations across molecular data types. ERVK9-11 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVK9-11 RNA expression–survival associations across cancer types. High ERVK9-11 expression shows unfavorable associations in MESO, LGG and CESC, but favorable associations in UVM, KIRC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for ERVK9-11 RNA expression.
This table summarizes ERVK9-11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ERVK9-11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVK9-11 shows lower tumor expression in KICH, UCEC, THCA, KIRP and BRCA and higher tumor expression in KIRC. The KICH box plot shows higher ERVK9-11 RNA expression in normal versus tumor tissue (log2 FC = −1.565, t-test p < 0.001).
This table shows molecular features associated with ERVK9-11 in patient tissues and cancer cell lines. In patient samples, ERVK9-11 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
